News | March 16, 2026
First patient dosed in trial of novel drug targeting limb-threatening artery disease
The trial will enroll up to 42 patients in Finland across four cohorts
The trial will enroll up to 42 patients in Finland across four cohorts
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
The protections extend through at least 2035, with the potential for further extensions
The initiative will focus on creating healthier early-life environments, promoting physical activity, identifying risks early, and strengthening preparedness within primary health care systems
Nearly 12 million people are estimated to be living with glaucoma, making the country one of the worst affected globally
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation
Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
Subscribe To Our Newsletter & Stay Updated
